Drugs / OCTA101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04046848 | Jul 2019 → Feb 2022 | severe hemophilia A | Octapharma | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-07-04 | Octapharma | Results Octapharma shares new data at ISTH2022 in its mission to meet the challenges faced by people with bleeding disorders octapharma.com ↗
The safety and immunogenicity results from the phase I/II study of OCTA101, a recombinant FVIII developed for subcutaneous administration, will also be presented, following the recent decision to terminate the study due to safety concerns. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-07-04 | Octapharma | Octapharma shares new data at ISTH2022 in its mission to meet the challenges faced by people with bleeding disorders octapharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCTA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04046848 ↗ |
| Modality | Protein / enzyme biologic | “OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).” NCT04046848 ↗ |
| Route | Subcutaneous | “subcutaneous injection of OCTA101” NCT04046848 ↗ |